Elanco Animal Health (ELAN) Stock Price, News & Analysis

Company Overview

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Key Stats

• Today's Range: $13.84 to $14.40
• 50-Day Range: $12.38 to $15.47
• 52-Week Range: $10.19 to $18.80
• Volume: 6.32 million shs
• Average Volume: 4.40 million shs
• Market Capitalization: $6.96 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.14
• Consensus Rating: Hold

Elanco Animal Health Stock Analysis - MarketRank™

Elanco Animal Health scored higher than 71% of companies evaluated by MarketBeat, and ranked 330th out of 969 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Hold

Consensus Rating

Elanco Animal Health has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 4 buy ratings, 2 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Elanco Animal Health has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: 3.30%

Earnings Growth

Earnings for Elanco Animal Health are expected to grow by 3.30% in the coming year, from $0.91 to $0.94 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Elanco Animal Health is -5.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Elanco Animal Health is -5.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Elanco Animal Health has a PEG Ratio of 1.34. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Elanco Animal Health has a P/B Ratio of 1.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.33% of the outstanding shares of Elanco Animal Health have been sold short.

Short Interest Ratio / Days to Cover

Elanco Animal Health has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Elanco Animal Health has recently decreased by 7.25%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Elanco Animal Health does not currently pay a dividend.

Dividend Growth

Elanco Animal Health does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 0.3 / 5
• Environmental Score: -4.69

Percentage of Shares Shorted

2.33% of the outstanding shares of Elanco Animal Health have been sold short.

Short Interest Ratio / Days to Cover

Elanco Animal Health has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Elanco Animal Health has recently decreased by 7.25%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: 0.13

News Sentiment

Elanco Animal Health has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.37 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 43 news articles for Elanco Animal Health this week, compared to 10 articles on an average week.

Search Interest

Only 5 people have searched for ELAN on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Elanco Animal Health to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Elanco Animal Health insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,352,975.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 0.57% of the stock of Elanco Animal Health is held by insiders.

Percentage Held by Institutions

97.48% of the stock of Elanco Animal Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ELAN Stock Analysis - Frequently Asked Questions

How have ELAN shares performed this year?

Elanco Animal Health's stock was trading at $14.90 on January 1st, 2024. Since then, ELAN shares have decreased by 5.6% and is now trading at $14.07.
View the best growth stocks for 2024 here.

How were Elanco Animal Health's earnings last quarter?

Elanco Animal Health Incorporated (NYSE:ELAN) issued its quarterly earnings results on Thursday, November, 7th. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.12 by $0.01. The firm's quarterly revenue was down 3.6% on a year-over-year basis.

When did Elanco Animal Health IPO?

Elanco Animal Health (ELAN) raised $1.4 billion in an IPO on Thursday, September 20th 2018. The company issued 62,900,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Barclays, BNP PARIBAS, BofA Merrill Lynch, Citigroup, Credit Suisse, Deutsche Bank Securities, Evercore ISI, Cowen, Academy Securities, Drexel Hamilton, Mischler Financial Group, Ramirez and The Williams Capital Group were co-managers.

Who are Elanco Animal Health's major shareholders?

Top institutional shareholders of Elanco Animal Health include Primecap Management Co. CA (10.64%), Douglas Lane & Associates LLC (0.76%), Assenagon Asset Management S.A. (0.31%) and Private Management Group Inc. (0.29%). Insiders that own company stock include R David Hoover, Jeffrey N Simmons, Michael J Harrington, John P Bilbrey and Rajeev A Modi.
View institutional ownership trends.

How do I buy shares of Elanco Animal Health?

Shares of ELAN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Elanco Animal Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Elanco Animal Health investors own include Salesforce (CRM), Home Depot (HD), Chevron (CVX), Pfizer (PFE), Bank of America (BAC), QUALCOMM (QCOM) and AbbVie (ABBV).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 11/10/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 2/24/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:ELAN
• CUSIP: N/A
• CIK: 1739104
• Web: www.elanco.com
• Phone: (877) 352-6261
• Fax: N/A
• Employees: 9,300
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $17.14
• High Stock Price Target: $20.00
• Low Stock Price Target: $14.00
• Potential Upside/Downside: +21.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.55)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 15.46
• P/E Growth: 1.34
• Net Income: $-1,231,000,000.00
• Net Margins: -27.94%
• Pretax Margin: -27.69%
• Return on Equity: 7.29%
• Return on Assets: 3.14%

Debt

• Debt-to-Equity Ratio: 0.92
• Current Ratio: 2.93
• Quick Ratio: 1.75

Sales & Book Value

• Annual Sales: $4.42 billion
• Price / Sales: 1.57
• Cash Flow: $2.52 per share
• Price / Cash Flow: 5.59
• Book Value: $12.63 per share
• Price / Book: 1.11

Miscellaneous

• Outstanding Shares: 494,330,000
• Free Float: 491,507,000
• Market Cap: $6.96 billion
• Optionable: Optionable
• Beta: 1.41